Announcements Trials
Browse Landscape

Phase

Phase 2 41Phase 1/2 6Phase NA 5Phase 3 2Phase 4 1Phase 2/3 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myeloid, Acute 19Leukemia 16Myelodysplastic Syndromes 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neuroblastoma 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Erythroblastic, Acute 3Congenital Abnormalities 3Sarcoma, Ewing 2Neoplasms, Plasma Cell 2Myeloproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Lymphocytic, Chronic, B-Cell 2Graft vs Host Disease 2Burkitt Lymphoma 2Anemia, Refractory, with Excess of Blasts 2Sarcoma 1Recurrence 1

Interventions

ruxolitinib 6Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Cytarabine 5fludarabine phosphate 4Whole-Body Irradiation 4Methotrexate 4Daunorubicin 4Thioguanine 3Tacrolimus 3Etoposide 3Early Intervention, Educational 3Cyclophosphamide 3ponatinib 2parsaclisib 2nilotinib 2merphos 2luspatercept 2fludarabine 2fedratinib 2anagrelide 2Tretinoin 2Therapeutics 2Psychiatric Rehabilitation 2Mitoxantrone 2Filgrastim 2Cyclosporins 2Cyclosporine 2Busulfan 2Asparaginase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Myeloproliferative Disorders × Busulfan × Clear all
NCT01366612 2026-04-03

FLUBUTBI

Hackensack Meridian Health

Phase 3 Terminated
53 enrolled 11 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT00322101 2014-10-31

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Fred Hutchinson Cancer Center

Phase 3 Completed
25 enrolled 13 charts
MyeloidOther hematologic neoplasm

Chromosome 5q Deletion Syndrome, Myeloproliferative Syndrome, Transient, Congenital Abnormalities, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡